-
Something wrong with this record ?
An Observational Pilot Study using a Digital Phenotyping Approach in Patients with Major Depressive Disorder Treated with Trazodone
J. Čermák, S. Pietrucha, A. Nawka, P. Lipone, A. Ruggieri, A. Bonelli, A. Comandini, A. Cattaneo
Status not-indexed Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2009
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- Publication type
- Journal Article MeSH
This 8-week study was designed to explore any correlation between a passive data collection approach using a wearable device (i.e., digital phenotyping), active data collection (patient's questionnaires), and a traditional clinical evaluation [Montgomery-Åsberg Depression Rating Scale (MADRS)] in patients with major depressive disorder (MDD) treated with trazodone once a day (OAD). Overall, 11 out of 30 planned patients were enrolled. Passive parameters measured by the wearable device included number of steps, distance walked, calories burned, and sleep quality. A relationship between the sleep score (derived from passively measured data) and MADRS score was observed, as was a relationship between data collected actively (assessing depression, sleep, anxiety, and warning signs) and MADRS score. Despite the limited sample size, the efficacy and safety results were consistent with those previously reported for trazodone. The small population in this study limits the conclusions that can be drawn about the correlation between the digital phenotyping approach and traditional clinical evaluation; however, the positive trends observed suggest the need to increase synergies among clinicians, patients, and researchers to overcome the cultural barriers toward implementation of digital tools in the clinical setting. This study is a step toward the use of digital data in monitoring symptoms of depression, and the preliminary data obtained encourage further investigations of a larger population of patients monitored over a longer period of time.
Angelini Pharma S p A Rome Italy
Centrum Duševního Zdraví Psychiatrie s r o Kutná Hora Czechia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010120
- 003
- CZ-PrNML
- 005
- 20230721095323.0
- 007
- ta
- 008
- 230707s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fpsyt.2023.1127511 $2 doi
- 035 __
- $a (PubMed)37032913
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Čermák, Jan $u Psychiatrie Říčany s.r.o., Říčany, Czechia
- 245 13
- $a An Observational Pilot Study using a Digital Phenotyping Approach in Patients with Major Depressive Disorder Treated with Trazodone / $c J. Čermák, S. Pietrucha, A. Nawka, P. Lipone, A. Ruggieri, A. Bonelli, A. Comandini, A. Cattaneo
- 520 9_
- $a This 8-week study was designed to explore any correlation between a passive data collection approach using a wearable device (i.e., digital phenotyping), active data collection (patient's questionnaires), and a traditional clinical evaluation [Montgomery-Åsberg Depression Rating Scale (MADRS)] in patients with major depressive disorder (MDD) treated with trazodone once a day (OAD). Overall, 11 out of 30 planned patients were enrolled. Passive parameters measured by the wearable device included number of steps, distance walked, calories burned, and sleep quality. A relationship between the sleep score (derived from passively measured data) and MADRS score was observed, as was a relationship between data collected actively (assessing depression, sleep, anxiety, and warning signs) and MADRS score. Despite the limited sample size, the efficacy and safety results were consistent with those previously reported for trazodone. The small population in this study limits the conclusions that can be drawn about the correlation between the digital phenotyping approach and traditional clinical evaluation; however, the positive trends observed suggest the need to increase synergies among clinicians, patients, and researchers to overcome the cultural barriers toward implementation of digital tools in the clinical setting. This study is a step toward the use of digital data in monitoring symptoms of depression, and the preliminary data obtained encourage further investigations of a larger population of patients monitored over a longer period of time.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pietrucha, Slavomír $u Centrum Duševního Zdraví-Psychiatrie s.r.o., Kutná Hora, Czechia
- 700 1_
- $a Nawka, Alexander $u Institut Neuropsychiatrické Péče (INEP) (Psychiatric Outpatient Clinic), Praha, Czechia
- 700 1_
- $a Lipone, Paola $u Angelini Pharma S.p.A., Rome, Italy
- 700 1_
- $a Ruggieri, Alessandro $u Angelini Pharma S.p.A., Rome, Italy
- 700 1_
- $a Bonelli, Annalisa $u Angelini Pharma S.p.A., Rome, Italy
- 700 1_
- $a Comandini, Alessandro $u Angelini Pharma S.p.A., Rome, Italy
- 700 1_
- $a Cattaneo, Agnese $u Angelini Pharma S.p.A., Rome, Italy
- 773 0_
- $w MED00174602 $t Frontiers in psychiatry $x 1664-0640 $g Roč. 14, č. - (2023), s. 1127511
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37032913 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230707 $b ABA008
- 991 __
- $a 20230721095317 $b ABA008
- 999 __
- $a ok $b bmc $g 1958638 $s 1196384
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 14 $c - $d 1127511 $e 20230324 $i 1664-0640 $m Frontiers in psychiatry $n Front Psychiatry $x MED00174602
- LZP __
- $a Pubmed-20230707